Oncology - European Medical Journal

Continue

Oncology

Filter
EMJ
26 Jun 2015

Novel JAK Inhibitor Pacritinib Proves Effective for Easing Symptoms of Myelofibrosis

Findings from the PERSIST-1 study of patients with myelofibrosis suggest that pacritinib is significantly more effective than best available therapy…
EMJ
26 Jun 2015

Obinutuzumab Doubles Remission Duration in Relapsed, Indolent Non-Hodgkin Lymphoma

Interim analysis of a phase III study finds that adding the new anti-CD20 monoclonal antibody obinutuzumab to standard bendamustine chemotherapy…
EMJ
26 Jun 2015

Daratumumab Shows Promise in Heavily Treatment-Resistant Multiple Myeloma

A phase II trial suggests that anti-CD38 antibody daratumumab is effective as a standalone therapy for heavily treated multiple myeloma. In a group of…
EMJ
26 Jun 2015

New Ibrutinib Combination Regimen Shows Substantial Benefits in Relapsed CLL

An interim analysis of a large phase III study suggests that the combination of ibrutinib and bendamustine/rituximab (BR) improves outcomes for patients…
EMJ
2 Jun 2015

Genomic Marker Predicts Anti-PD-1 Response in Several Cancers

A phase II study identified the first genomic marker – mismatch repair (MMR) deficiency – to predict response to the anti-PD-1 antibody pembrolizumab…
EMJ
2 Jun 2015

Nivolumab Extends Survival for Patients With the Most Common Lung Cancer

Findings from a randomised phase III study indicate that PD-1 immunotherapy is an effective treatment option for patients with non-squamous, non-small…
EMJ
2 Jun 2015

An introduction to ASCO 2015 by the 2014-15 president, Peter Paul Yu, MD, FACP, FASCO

Peter Paul Yu, MD, FACP, FASCO introduces ASCO 2015 and the conference themes – how to utilise data, to transform it into learning to impact patient care.
EMJ
21 May 2015

PARP inhibitors and the EMBRACA study of talazoparib in BRCA-related metastatic breast cancer

At the 14th St. Gallen International Breast Cancer Conference 2015, Prof. Dr. med. Peter Fasching (Friedrich-Alexander-Universität Erlangen-Nürnberg…